https://scholars.lib.ntu.edu.tw/handle/123456789/588816
標題: | Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: Incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia | 作者: | Yang J.-J. Huang C.-H. Liu C.-E. Tang H.-J. Yang C.-J. Lee Y.-C. Lee K.-Y. Tsai M.-S. SHU-WEN LIN Chen Y.-H. Lu P.-L. CHIEN-CHING HUNG |
公開日期: | 2014 | 出版社: | Public Library of Science | 卷: | 9 | 期: | 9 | 起(迄)頁: | e106141 | 來源出版物: | PLoS ONE | 摘要: | The incidence of hepatotoxicity related to trimethoprim/sulfamethoxazole (TMP/SMX) administered at a therapeutic dose may vary among study populations of different ethnicities and hepatotoxic metabolites of TMP/SMX may be decreased by drug-drug interaction with fluconazole. We aimed to investigate the incidence of hepatotoxicity and the role of concomitant use of fluconazole in HIV-infected patients receiving TMP/SMX for Pneumocystis jirovecii pneumonia. We reviewed medical records to collect clinical characteristics and laboratory data of HIV-infected patients who received TMP/SMX for treatment of P. jirovecii pneumonia at 6 hospitals around Taiwan between September 2009 and February 2013. Hepatotoxicity was defined as 2-fold or greater increase of aminotransferase or total bilirubin level from baselines. Roussel UCLAF Causality Assessment Method (RUCAM) was used to analyze the causality of drug-induced liver injuries. NAT1 and NAT2 acetylator types were determined with the use of polymerase-chain-reaction (PCR) restriction fragment length polymorphism to differentiate common single-nucleotide polymorphisms (SNPs) predictive of the acetylator phenotypes in a subgroup of patients. During the study period, 286 courses of TMP/SMX treatment administered to 284 patients were analyzed. One hundred and fifty-two patients (53.1%) developed hepatotoxicity, and TMP/SMX was considered causative in 47 (16.4%) who had a RUCAM score of 6 or greater. In multivariate analysis, concomitant use of fluconazole for candidiasis was the only factor associated with reduced risk for hepatotoxicity (adjusted odds ratio, 0.372; 95% confidence interval, 0.145-0.957), while serostatus of hepatitis B or C virus, NAT1 and NAT2 acetylator types, or receipt of combination antiretroviral therapy was not. The incidence of hepatotoxicity decreased with an increasing daily dose of fluconazole up to 4.0 mg/kg. We conclude that the incidence of TMP/SMX-related hepatotoxicity was 16.4% in HIV-infected Taiwanese patients who received TMP/SMX for pneumocystosis. Concomitant use of fluconazole was associated with decreased risk for TMP/SMX-related hepatotoxicity. ? 2014 Yang et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906968534&doi=10.1371%2fjournal.pone.0106141&partnerID=40&md5=04f1f693e7f1fdbabd7d01c31cc348af https://scholars.lib.ntu.edu.tw/handle/123456789/588816 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0106141 | SDG/關鍵字: | aminotransferase; arylamine acetyltransferase; bilirubin; cotrimoxazole; fluconazole; noradrenalin transporter; anti human immunodeficiency virus agent; antiinfective agent; arylamine acetyltransferase; cotrimoxazole; fluconazole; isoenzyme; N-acetyltransferase 1; NAT2 protein, human; acetylator phenotype; acute kidney failure; acute psychosis; adult; adverse outcome; aged; Article; clinical feature; esophagus candidiasis; female; Hepatitis B virus; Hepatitis C virus; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; hyperkalemia; hyponatremia; incidence; leukopenia; liver toxicity; major clinical study; male; medical record review; multicenter study; nausea and vomiting; outcome assessment; Pneumocystis pneumonia; polymerase chain reaction; rash; restriction fragment length polymorphism; retrospective study; risk reduction; Roussel UCLAF Causality Assessment Method score; scoring system; single nucleotide polymorphism; Taiwan; very elderly; young adult; clinical trial; complication; drug effects; drug interaction; Drug-Induced Liver Injury; gene expression; genetics; HIV Infections; Human immunodeficiency virus; liver; metabolism; middle aged; multivariate analysis; pathology; physiology; Pneumocystis jiroveci; Pneumonia, Pneumocystis; virology; Pneumocystis jirovecii; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Anti-Infective Agents; Arylamine N-Acetyltransferase; Drug Interactions; Drug-Induced Liver Injury; Female; Fluconazole; Gene Expression; HIV; HIV Infections; Humans; Isoenzymes; Liver; Male; Middle Aged; Multivariate Analysis; Pneumocystis jirovecii; Pneumonia, Pneumocystis; Polymorphism, Single Nucleotide; Retrospective Studies; Trimethoprim-Sulfamethoxazole Combination |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。